Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced it received regulatory approval to initiate KLARITY, a Phase 2 clinical trial to investigate KIO-104 in patients ...

Bayer seeks European approval of extended 6-month treatment interval for Eylea 8 mg to treat nAMD & diabetic macular edema: Berlin Tuesday, February 11, 2025, 10:00 Hrs [IST] Baye ...

February is Age-Related Macular Degeneration Awareness (AMD) month. While AMD might be unfamiliar to some, nearly half a million people in Quebec are affected by this disease, which is the leading ...

Regeneron Pharmaceuticals has announced results from the phase 3 QUASAR trial and its extension study of the phase 3 PULSAR ...

Loss to follow-up higher among men who are Black or Hispanic, or those who must travel farther to care facilities.

D Molecular Therapeutics reported 52-week Phase 2b data for 4D-150 in wet AMD, showing sustained visual acuity improvements.

As people get older, two of the biggest health concerns are dementia and eye diseases like macular degeneration and cataracts ...

ALPHARETTA, Ga. - Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company with a market capitalization of $85.7 million focused on developing therapies for ocular diseases, has announced ...

For those who smoke, this long-term habit can damage parts of your eye, contributing to serious conditions such as macular degeneration. According to experts, AMD has no cure and can only worsen over ...

Bayer submitted an application to the European Medicines Agency (EMA) to expand treatment intervals of up to 6 months with Eylea™ 8 mg (aflibercept 8 mg, ...

Hong Kong biotech start-up works with university partners to conduct global clinical trials studying prevalent eye diseases.

Macular degeneration is a condition that affects the retina, which is neural tissue that lines the back of the eye, like wallpaper in a room. There is an important area ...